The proresilients in multimodal programmes for the prevention of premature ageing
Background: Premature ageing is a common process. According to various authors, at least 10-20% of middle-aged people have unfavorable levels of discrepancy between biological and passport age. That is why the preventive direction is actively developing in gerontology. Various substances like the proresilients, for example, are actively studied for their geroprotective properties in terms of their impact on cellular mechanisms of premature ageing. The aim of the study: To study the properties of the proresilients in multimodal programs for the prevention of premature ageing. Materials and methods: We studied literary figures for 2015-2020 in computer databases, PubMed, Medical-Science, Elibrary, Ceeol, JSTOR, Web of Science, Scopus. Results: The proresilients are used in various programs for improving the body and reducing the aging process of cells, reducing oxidative stress and other pathological mechanisms. They act at the level of the cell so they can slow down the destruction of organs and balance systems. This is due to their positive effect on the entire body and the patient's well-being. The proresilients have the criteria of a good pharmaceutical practices and quality criteria of 4G. The application of the proresilients is important in three areas of medicine like cosmetology, anti-ageing and preventive medicine. Age-related skin changes are inevitable, but it is important to take measures to prevent premature ageing. That’s why it`s important to use the proresilients to prevent skin changes and premature ageing. Conclusion: In conclusion, the proresilients is a new, actively developed group of nutraceutical drugs that can be successfully used in modern health management technologies in multi-modal prevention and rehabilitation programs.
Rubikas V, Piatryshcha T, Rozhdestvenskaya O, et al. The proresilients in multimodal programmes for the prevention of premature ageing. Research Results in Biomedicine. 2020;6(3):397-401.
DOI: 10.18413/2658-6533-2020-6-3-0-9
While nobody left any comments to this publication.
You can be first.